ESMO 2018 - 19-23 October, 2018
19 October 2018
Showing 1428 posters
520. Comparison between the 7th and the proposed 8th editions of the UICC staging system for nasopharyngeal carcinoma patients without cervical lymph node metastasis: a retrospective analysis
521. Patterns of Local Failures and Suggestions for Reduction of Clinical Target Volume for Nasopharyngeal Carcinoma Patients Without Cervical Lymph Node Metastasis
524. Prognostic impact of end-of-life chemotherapy in the last weeks for patients with advanced cancer
552. Comparison of microsatellite status detections in colorectal carcinoma
608. Outcome Following Centralisation of Pancreatic Cancer Care in Ireland
624. Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
628. Efficacy of metastasectomy on survival in patients with metachronous soft tissue sarcoma-metastasis. Results of a bi-centre study including 135 patients.
635. Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?
660. Can concomitant diseases predict the compliance with cisplatin plus RT in patients with LA SCCHN? An exploratory endpoint analysis of the COMPLY trial.
665. Survival from breast cancer in patients with BRCA1/2, CHEK2, NOD2 mutations and TP53 (c.[215G>C]) polymorphisms.
666. Painkiller-related dizziness in malignant tumors - A systematic review
673. Partners’ perceptions of women’s body image problems and satisfaction of breast reconstruction long-term after risk-reducing mastectomy
711. A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht).
715. Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
716. Predicting the occurrence and prevention of early anthracycline cardiotoxicity of chemotherapy in patients with breast cancer
723. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma
738. Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
749. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
752. The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study
762. Incidence of Immune Related Adverse Events in patients 70 years old treated with anti-PD-(L)1 therapy
766. HER2 staining intensity has prognostic impact on patients with HER2 type invasive breast cancer
767. Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro
770. Avelumab in Newly Diagnosed Glioblastoma Multiforme - The SEJ Study
785. Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma
819. Effects of Physical Exercise in non-operable lung cancer patients undergoing palliative treatment
829. Neoadjuvant radio-chemotherapy for esophageal cancer: a multicenter european study comparing PACLITAXEL/CARBOPLATIN , 5FU/CISPLATIN and FOLFOX.
832. Individual genetic variation could predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy
834. Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by stereotactic body radiation therapy
835. Current use of clinical nutrition in oncology patients – real world evidence from big data in Italy
843. Opioid-induced Constipation in Patients with Cancer Pain in Japan: Prospective Observational Study Using Rome IV OIC Diagnostic Criteria (OIC-J Study)
846. Genomic characteristics of standardized uptake value of 18F-fluorodeoxy-glucose positron emission tomography in breast cancer
850. A multicenter study of mutational profiling of Chinese ALK+ non-small cell lung cancer patients with required resistant to crizotinib using next generation sequencing
868. Outcomes of Chemoradiotherapy plus Local Excision in Patients with Clinical T1 or T2, N0 Rectal Cancer
869. Evaluate the Role of Induction Chemotherapy in the Treatment of Stage II Nasopharyngeal Carcinoma in Intensity Modulated Radiotherapy Era
876. Target delineation and dose prescription for adaptive replanned intensity-modulated radiotherapy in nasopharyngeal carcinoma.
879. Transmural collaborative care in oncology: Experiences of general practitioners
892. Elective nodal irradiation as adjuvant radiotherapy for advanced thymomas and thymic carcinomas
894. Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo
900. The Role of Neurotrophic Factors in Nerve-Cancer Crosstalk
926. Group Pre-Chemotherapy Education: Improving patient experience through education and empowerment
934. Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: a real-world prospective study
938. MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1
946. Influenza vaccine effectiveness among cancer patients: a population-based study using health administrative and laboratory testing data from Ontario, Canada
950. Distribution of Endocrine Tumor Marker-positive Cells in Adenocarcinoma Tissue Between Right-sided and Left-sided Colon Cancer
953. A Phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies
954. Quality of Life in patients with soft tissue sarcoma undergoing palliative treatment - A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12)
965. Inhibitory Effect of a Synthetic Bioresorbable Adhesion Membrane (Seprafilm®) on Small Bowel Obstruction (SBO) in Patients Undergoing Elective Surgery for Colon Cancer :a Randomized Controlled Trial
966. Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
977. Effectiveness of a Randomized Control Trial of an Individualized, Interactive Advance Care Planning Intervention in Improving Terminally Ill Cancer Patients’ Psychological Symptoms, Quality of Life and Concordance between Preferred and Received Life-Sustaining Treatments
999. Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: survival results from a phase II feasibility study (NAVAL)
1002. Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort
1004. A randomized phase III study to evaluate the value of the omission of prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601)
1006. Cancer Associated Thrombosis with Primary Prophylaxis in a Tertiary Hospital in the Philippines from 2010-2015
1015. Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer (ICAR)
1018. Meta-enrichment analysis to identify a higher response patient population to S-1/Cisplatin for advanced gastric cancer
1022. Breast cancer treatment waiting time, Patient and provider contributions; An Egyptian breast cancer centre experience
1026. Influence of not having children on mortality in patients with metastatic (mCRC) colorectal cancer.
1028. Impaired survival in resected glioblastoma multiforme patients treated with early chemoradiation.
1031. Analysis of characteristics of second primary cancer in 300 000 electronic patient records of a French comprehensive cancer center using Data-mining with the ConSoRe tool.
1036. Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations.
1039. The Safety and Efficacy of Durvalumab in Combination with Paclitaxel for the treatment of Metastatic Triple Negative Breast Cancer
1042. A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease
1044. A Randomized Phase III Study of Denosumab before Curettage for Giant Cell Tumor of Bone: Japan Clinical Oncology Group Study JCOG1610
1052. IMvoke010: Randomized Phase III Study of Atezolizumab (atezo) as Adjuvant Monotherapy After Definitive Therapy of Squamous Cell Carcinoma of the Head and Neck (SCCHN)
1057. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)
1058. Patients - power sources for cancer nurses
1064. Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): results of a placebo-controlled, randomized, double-blind phase 2 study
1069. Safety profile and effectiveness of alectinib in the real world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer
1070. Exploring the effectiveness of crisis counselling and psycho-education in relation to improving mental wellbeing, quality of life and treatment compliance of breast cancer patients in Qatar
1074. Is There a Difference in PFS or OS of T790M-Mutated NSCLC Patients Treated with Osimertinib either after Chemotherapy or Immediately after Previous Target Therapy?
1075. Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial)
1083. Malignant lymphoma detected by screening program with esophagogastroduodenoscopy of one private screening center in Japan
1088. Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
1095. The Clinical Impact of Targeted Next Generation Sequencing (tNGS) In the Treatment of Metastatic Prostate Cancer
1106. Evaluation of the distinction and temporal relationship between prolonged grief disorder and depression in terminally ill cancer patients’ caregivers’ first two years of bereavement
1109. A Longitudinal Study of a New Point-of-Care Nerve Conduction Device for Quantitative Assessment of Chemotherapy-Induced Peripheral Neurotoxicity
1110. Relationship between change in α-fetoprotein (AFP) and patient (pt) survival in hepatocellular carcinoma (HCC): a real-world electronic medical records (EMR) database study
1115. Potential Survival Gains from First-Line (1L) Systemic Therapy Advances in Metastatic Triple-Negative Breast Cancer (mTNBC)
1119. Anti-hypertensive medication, sRAGE, and risk of pancreatic cancer: results from the Women’s Health Initiative Study
1123. Childhood gliomas diagnosed during 2000-2014 (CONCORD-3): worldwide morphology distribution
1133. Residential radon and small cell lung cancer. A systematic review.
1142. ABCB1 Genetic Polymorphism and Pharmacokinetic Analysis of Low Dose Erlotinib in Frail Patients with EGFR Mutation (mt) -positive, Non-small Cell Lung Cancer: TORG1425
1147. Major determinants of delayed access to innovative medicines for metastatic melanoma: the results of Melanoma World Society and European Association of Dermato-oncology survey
1151. Phase 1 study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors
1156. Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: the FFCD 1104-EVACEL-GTE phase II study
1159. Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
1161. A randomized phase 2 trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
1162. A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who in participated US National Cancer Institute Cooperative Group studies
1165. Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients
1175. Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
1178. Current status of the integration of oncology and palliative care in Japan: A nationwide survey.
1179. Perspectives and attitudes towards the integration of oncology and palliative care in Japan: A nationwide survey.
1196. Phase II study of paclitaxel and TAK-228 in metastatic urothelial carcinoma and the impact of PI3K-mTOR pathway genomic alterations
1199. Socioeconomic disparities in referral to phase 1 cancer clinical: A Danish matched case - cancer control study
1202. RANGE, a phase 3, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): overall survival results
1204. Multiobjective optimization reveals distinct cancer-testis antigen patterns by primary site and Human Papilloma Virus status in head and neck squamous cell carcinoma
1206. Medical-Aid-in-Dying Use in the US Pacific Northwest
1207. Chemotherapy effect on daytime sleepiness and contributing factors in older adults with cancer
1215. Cisplatin in NIPEC or HIPEC?
1218. The efficacy of eribulin for patients with taxane-resistant cutaneous angiosarcoma: interim result of multi-center, prospective observational study.
1221. Timing of treatment in Small Cell Lung Cancer
1223. Potential Therapeutic Targets in Recurrent and Metastatic Parathyroid Carcinomas revealed by next-generation sequencing.
1229. Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer
1235. Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
1238. Population-based use of intravenous bisphosphonates in patients newly diagnosed with symptomatic multiple myeloma in Denmark in 2005-2015: impact of patient characteristics
1259. Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance
1260. Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance
1261. A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with recurrent ovarian cancer treated with poly adenosine diphosphate ribose polymerase inhibitors maintenance
1262. Incidence of cardiac toxicities in patients with advanced non-small-cell lung cancer treated with osimertinib: a combined analysis of two phase III randomized controlled trials
1276. Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) + FOLFIRI – Efficacy according to age group ≤65 and >65 years
1281. OT-1096, a first-in-class immunoactivating small molecule that targets the thioredoxin reductase/thioredoxin axis causes strong tumor growth inhibition by downregulating intratumoral Tregs in a humanized TNBC-PDX model.
1282. Patients’ learning and participation in their breast cancer care
1297. Characterization of PD-L1, CD8, CD3, CD68 and PanCK in Tumor Microenvironment of Gl Tract Tumors with respect to Patients’ Mismatch Repair Status and Anti-PD-1 Treatment Outcome using 5Plex IHC and Whole Slide Image Analysis
1300. Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location
1304. Increase in tumor-infiltrating FoxP3-positive regulatory T cells in left-sided colorectal cancer tissues after preoperative oral uracil and tegafur/leucovorin chemotherapy
1307. Brain Metastases in Norway - A Prospective Cohort Study
1310. Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors
1314. Final results of the concordance analysis of PD-L1 immunohistochemistry (IHC) assays and polymerase chain reaction (PCR) in non-small lung cancer (NSCLC) patients
1321. Multicenter Feasibility Study of Physician Orders for Life-Sustaining Treatment (POLST) for Terminal Cancer Patients
1324. Efficacy and safety of nivolumab for cytotoxic chemotherapy unfit patients with advanced non-small cell lung cancer: A phase II study
1327. Plinabulin (Plin), a Novel non-G-CSF Molecule for the Prevention of Chemotherapy-Induced Neutropenia (CIN), has the Potential to Positively Impact Tumor Micro Environment
1330. KS In The Era Of HAART: A Single Institutional Retrospective Review
1332. Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients
1337. Clinical Benefit of Whole Genome and Transcriptome Analysis (WGTA) in Metastatic Colorectal Cancer (MCRC): Results from the Personalized Oncogenomics Program (POG)
1343. FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)
1344. The results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy
1352. Response evaluation of cancer therapeutics in metastatic breast cancer to the bone: a single arm phase 2 study of whole-body magnetic resonance imaging
1358. Role of Liposomal Doxorubicin as a first line agent with VTd regimen in newly diagnosed Multiple Myeloma
1367. HBP-bound doxorubicin: promising new therapy for bone cancer
1371. Prospective observational study to evaluate the persistence of treatment with denosumab (dmab) in patients (pts) with bone metastases (BM) from solid tumors (ST) in routine clinical practice: final analysis
1372. Access to Palliative Care before death in French cancer patients during the two first years after diagnosis: the national cancer cohort
1373. Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: a phase II randomized study (JBCRG-19)
1375. High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4
1389. A Phase 1b Study of Navicixizumab & Weekly Paclitaxel in Heavily Pre-Treated Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
1398. Clinical utility of hepatic arterial infusion chemotherapy for heavily pretreated metastatic breast cancer patients: A review of a single institution
1399. mechanisms of G9a on promoting tumor invasion and metastasis of gastric cancer
1404. Gefitinib With or Without Pemetrexed in Nonsquamous (NS) Non–Small Cell Lung Cancer (NSCLC) With EGFR Mutation (mut): Final Overall Survival (OS) Results From a Randomized Phase II Study
1408. Patient reports of mouth symptoms after radiotherapy treatment for head and neck cancer: an international survey.
1418. Elderly patients with locally advanced head and neck squamous cell carcinoma treated with NBTXR3 nanoparticles activated by radiotherapy: a phase I trial.
1419. Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass
1424. EXPRESS study - A Multicenter, Prospective Trial In Progress Exploring The Association Between Low Level Of Genomic Alteration And Exceptional And Unexpected Response To Targeted Therapies In Patients With Solid Tumors
1428. Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations
1436. Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)
1438. A multicenter retrospective investigation on the efficacy of perioperative oral management in cancer patients
1445. Efficacy and Tolerability of Naldemedine in Patient with Cancer and Opioid-Induced Constipation: A Pooled Subgroup Analysis of 2 Randomized Placebo Controlled Studies
1446. IMPACT OF GENETIC POLYMORPHISMS ON PROGNOSIS AND SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA
1449. Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
1457. Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: an explorative randomized AIO phase II trial (ACCEPT)
1459. Pharmacokinetic/Pharmacodynamic relationship of Enzalutamide and its active metabolite N-desmethyl Enzalutamide in metastatic castration-resistant prostate cancer patients
1463. CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)
1464. Prognostic factors associated with prevalence of nausea, and time to development of nausea in patients receiving guideline-based anti-emetic prophylaxis. A prospective, observational, real world study.
1469. Clinical impact of Whey protein and Nutritional Counseling in Gastrointestinal cancer Patients
1472. A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer. (JCOG1607 HERB TEA study)
1473. First-in-Human trial design for W0101, a first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population
1484. Stereotactic Radiosurgery (SRS) for brain metastases (BM) from breast cancer (BC) – a single centre experience of factors influencing survival
1486. Bcl-2 proteins expression and response to Navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)
1490. Predictor of Effectiveness of Treatment Intensification on Overall Survival in Head and Neck Cancer (HNC)
1494. Interaction of Oncostatin M and its receptor OSMR promotes gastric cancer progression via STAT3/FAK/Src signaling
1500. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel.
1509. Use of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: findings from a large study in German clinical practice (PROTECT)
1519. Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS Study
1521. Establishment and validation of M1 stage subdivisions for patients with de novo metastatic breast cancer: a population-based study
1526. Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro
1527. Preliminary Results from a Phase 1 Study of GBR 1302, A Bispecific Antibody T-Cell Engager, in HER2 Positive Cancers
1532. Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
1533. Glutathione S-transferase M subfamily in TMZ-resistant glioblastoma cells
1535. A Serum miRNA Biomarker Panel for the Detection of Early Stage Non-Small Cell Lung Cancer
1537. Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma.
1542. SAKK 17/16: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial.
1543. A phase Ib/II study of Durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE).
1551. Circulating tumor DNA by next generation sequencing as a prognostic and predictive biomarker in metastatic colorectal cancer
1553. BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care
1555. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial
1563. Reproducibility of the mRECIST criteria for the assessment of HCC treated by anti- VEGFR therapy: Impact of readers’ expertise
1565. A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.
1577. Using MultiOmyx™ to analyze correlations between immunosuppressive cells and tumor-infiltrating lymphocytes in the pancreatic tumor microenvironment
1583. Prognostic factors in patients with uterine leiomyosarcoma: A multi‑institutional retrospective study from the Japanese Gynecologic Oncology Group
1589. The impact of serum microRNA-21 on outcome of diffuse large B-cell lymphoma patients
1591. Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer.
1593. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): a post hoc analysis of the WJOG4407G phase III study
1594. In-depth assessment of metastatic prostate cancer with high tumour mutational burden
1595. Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort.
1596. Oncogenes analysis using GO-based clustering
1597. A novel electronic tool to implement palliative sedation (PS) in a department of Oncologic Medicine
1598. Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors
1600. A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)
1603. Spatial Genomic Heterogeneity from Multi-Region Endoscopic Biopsies in Primary Gastric Cancer: Implications for Precision Therapy
1606. Analysis of BRCAness with MLPA in pancreatic ductal adenocarcinoma patients using FFPE sample obtained via EUS-FNAB
1609. The retrospective analysis of nephrotoxicity for cisplatin dose of CRT compared 100 mg/m2 to 80 mg/m2 for head and neck cancer (HNC) patients
1612. Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)
1615. The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review
1616. A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer. The AIRS study
1618. Metabolic Syndrome in Breast Cancer Patients: An Observational Study
1623. Metastatic colorectal signet-ring cell carcinoma : clinical, histological and molecular description from an AGEO French multicenter retrospective cohort
1634. Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
1641. Comprehensive analysis for immune profiles of tumor microenvironment in non-small cell lung cancers: Prognostic effect of immunomodulatory molecules
1644. Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SCCHN in clinical routine: Updated interim results of the prospective SOCCER study
1648. Phase I pharmacological study of continuous chronomodulated capecitabine treatment
1654. Identification of positively and negatively selected driver gene mutations associated with colorectal cancer with microsatellite instability
1655. Comparison of venous thromboembolism risk assessment models in patients receiving chemotherapy
1659. General and dedicated cancer emergency room: clinical and financial implications
1661. Practice Patterns and Deterioration of Liver Function after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): Final Analysis of OPTIMIS in Europe and Canada
1664. Phase 1 trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms
1666. Health-related quality of life in randomized controlled trials: a systematic review of prognostic significance
1668. Prognostic factors for critically ill patients with solid cancer tumors admitted to a medical intensive care unit.
1670. Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
1673. The prognostic value of different molecular subtypes of breast cancer in relation to Enhancer-of-zeste homologue 2 expression
1683. Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care?
1684. Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: subgroup analysis from the BELA trial
1688. Prospective Cohort Study of Real World Chemotherapy Sequence for Metastatic Breast Cancer (KBCRN A001: E-SPEC Study)
1690. Women oncologists participation at the Spanish Society of Medical Oncology (SEOM) annual meetings from 2009 to 2017 and their position at spanish scientific societies.
1692. The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
1697. TiNivo: Tivozanib combined with nivolumab: safety and efficacy in patients with metastatic renal cell carcinoma (mRCC).
1698. Pharmacokinetic analysis of concurrent administration of enzalutamide and crizotinib in patients with metastatic castration resistant prostate cancer
1701. Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): results of a GETUG multicenter phase II trial (Axipap)
1707. Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
1710. A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
1713. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
1714. The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET)
1715. A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML)
1719. Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
1721. The potential of patient reported outcomes in urothelial cancer patients receiving immuno- or chemotherapy – a feasibility study of electronic reporting in an aging and comorbid population.
1727. Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC (ASCEND-8)
1730. Safety analysis of proposed biosimilar pegfilgrastim in Phase I and Phase III studies
1733. Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase.
1735. Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)
1740. VSV-IFNβ-NIS intratumoral (IT) injection: a first-in-human (FIH), phase 1 study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors
1741. Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients
1742. A phase 1 study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer.
1746. Genetic testing of BRCA mutations in breast cancer across Europe: barriers and opportunities
1748. Novel Small-Molecule RORγ Agonist Immuno-oncology Agent LYC-55716: Safety and Efficacy in a Phase 2A Open-Label, Multicenter Trial
1756. Combination Therapy Optimization in Gastrointestinal Cancers using Multi-omic Molecular Profiling
1757. Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab.
1764. Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of therapy, age and dose modification
1767. A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC – the ETOP and EORTC SPLENDOUR trial.
1769. Initial treatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancer.
1771. Exhaustion of Platelet Kinetics and its Implication in Post-resection HCC Recurrence
1775. Cell free DNA and Hepatic Arterial Infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases.
1781. PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung.
1789. The significance of FMS-Like Tyrosine Kinase 3 surface receptor expression in acute myeloblastic leukemia and precursor B-acute lymphoblastic leukemia patients
1791. Predictive significance of tumour angiogenic and anti-angiogenic VEGF-A splice variants in patients with metastatic colorectal cancer
1807. Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group
1812. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH)
1813. Long-term Adverse Effects (AEs) after dose-escalation with High-Dose Rate Brachytherapy in combination with External Beam Radiation Therapy (BT/RT). Comparison to External Beam Radiation Therapy alone (RT)
1817. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer.
1820. Dose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: data from ALTER0303
1825. United in Fight against prOstate cancer registry (UFO): first results from a large, multi-center, prospective, longitudinal cohort study in Asia
1833. Expression of Sp17 and its association with clinicopathological parameters of breast cancer
1836. Clinical and Psychometric validation of the BreSAS Questionnaire for Symptom Assessment among Breast Cancer Survivors.
1842. Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response
1843. Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival?
1856. Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches
1865. The characteristics and clinical outcome of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's tertiary referral center.
1866. Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma (EGA) - the randomized phase 2 INTEGA trial (AIO STO 0217)
1869. The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced Biliary Tract Cancer.
1871. Incidence of clinically significant toxicities in patients with high endoxifen concentrations
1875. Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss Cohort Study
1876. Nutritional Support Dependence after Curative Chemoradiotherapy in Head and Neck Cancer: a Supplementary Analysis of a Phase II Trial (JCOG0706S1)
1877. Correlation beetween the expression of androgens receptor (RA) and histopathological characteristics and survival parameters of breast cancer
1882. A Phase II Trial of Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck
1883. Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): a systematic literature review (SLR)
1885. Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
1888. Clinical impact of 18F-FDG-PET/CT (PET/CT) in patients with oligometastatic disease (OMD) at a skin and gastrointestinal tumour unit.
1891. Developing a predictive model for chemotherapy related toxicities in older Asian adults.
1892. Results from NRG Oncology/NSABP protocol DMP-1: Physician Counseling
1900. A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3
1901. Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer
1904. Sidedness of the Primary Tumor on the Effect of TAS-102 for Refractory metastatic colorectal cancer
1905. A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.
1906. BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: results from a first-in-human, phase 1, dose-escalation study
1910. Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)
1920. TRIANgLE study (JCOG1510): A phase III study of tri-modality combination therapy with induction docetaxel (DOC), cisplatin (CDDP), 5-fluorouracil (FU) (DCF) vs definitive chemoradiotherapy (dCRT) for locally advanced unresectable squamous cell carcinoma (SCC) of the thoracic esophagus
1921. Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): the CIROCO study
1926. Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors.
1927. Folfiri-Aflibercept vs Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.
1933. Immune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: a systematic review and meta-analysis.
1948. Clinical study on the efficacy of apatinib treatment for advanced ovarian cancer after second-line chemotherapy failure
1952. A Survey on acceptable nomenclature in addressing patient needs among the delegates of a national conference on supportive medicine
1953. Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project.
1955. Acceptability in Cancer Outpatients of Completing Routine Assessments of Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) versus Other Patient Reported Symptom Outcome Tools
1957. Tumor molecular characteristics in patients (pts) with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) good (G) and intermediate/poor (I/P) risk
1958. A Survey on purview of palliative medicine services among the delegates of a national conference on supportive medicine
1959. Incidence and Survival among Young Women with Stage I-III Breast Cancer
1962. A survey on attitude towards Euthanasia among delegates of a national conference on supportive medicine
1974. Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study
1977. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G
1981. LURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer
1987. A positive correlation between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma
1989. Colon Cancer Molecular Subtype IntraTumoral Heterogeneity and its prognostic impact : An Extensive Molecular Analysis of the PETACC-8
1990. Is it appropriate to use a fixed prophylactic dose of enoxaparin for hospitalized cancer patients? Results from a prospective tertiary referral single center study
1992. Autologous dendritic-cell vaccine based on cancer-testis antigens “CaTeVac” in the treatment of soft tissue sarcoma
1995. Screening for hereditary cancers in patients with endometrial cancer revealed a high frequency of germline mutations in cancer predisposition genes
2002. Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy
2005. Concurrent cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy for p16-positive, locally advanced oropharyngeal cancer: A meta-analysis
2010. A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study).
2012. Randomized phase 2 study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small-cell lung cancer (CLEAR study)
2014. Computed tomography features of resected lung adenocarcinomas with spread through air spaces
2019. Usefulness of bone modifying agents for non-weight bearing bone metastasis in breast cancer.
2021. The prognostic value of DNA damage level in peripheral blood lymphocytes in germ cell cancer patients.
2023. Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study
2026. Fluoropyrimidine and Inflammatory Genes Promoter Methylation in Egyptian CRC patients
2031. The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Pancreatic Cancer.
2037. A Multi-Omic Analysis for Prospective Patient Stratification in Localised Colorectal Cancer (CRC).
2038. the impact of lymph node dissection on high risk versus low risk endometrial cancer
2042. Developing the liquid biopsy in gastroesophageal adenocarcinoma: Disease monitoring and detection of minimal residual disease
2048. Anti-tNASP antibodies as a diagnostic marker for malignant tumors
2049. Comparison of Treatment Outcomes and Tolerability of Patients with Recurrent (R) Nasopharyngeal Carcinoma (NPC) and Metastatic Disease at Diagnosis (M1) : A Retrospective Analysis
2050. Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with Pembrolizumab in the INSPIRE study
2055. Salient features of an indigenous integrated inpatient model of delivery of supportive medicine services - a narrative review
2062. Factors that influence oncology nutrition efficacy in breast cancer patients under antiestrogenic treatment
2063. ATR inhibition with radiation creates an inflammatory tumour microenvironment.
2068. A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).
2072. Randomized phase II multicenter study comparing modified PFE regimen with modified TPEx regimen in recurrent or metastatic squamous cell carcinoma of the head and neck: TEMPER study
2084. Sequencing of KRAS and NRAS in 1501 colorectal carcinomas reveals significant share of mutations, which are not included in common diagnostic kits
2086. Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a Phase 1 study
2092. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of early breast cancer patients: a systematic review and meta-analysis of randomized controlled trials
2093. INTERIM: A randomised phase II feasibility study of INTERmittent versus continuous dosing of targeted therapy In patients with BRAFV600 mutant advanced Melanoma
2096. A classifier of 53BP1, immune score and texture analysis of MRI images can predict pathological response to chemoradiotherapy in locally advanced rectal cancer
2100. NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)
2101. The value of chemotherapy in Stage II colon cancer: much less than we thought
2103. Perceptions of Rural Nurses Extending Their Role to Administer Chemotherapy
2111. Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
2115. NCI 9922: Phase 2 Study of Ibrutinib in Treatment-Refractory Distant Metastatic Cutaneous Melanoma (DMCM)
2116. miR-200s in operated NSCLC: main drivers of epithelial to mesenchymal transition and independent prognostic factors
2117. Non-metastatic castration-resistant prostate cancer (nmCRPC): meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide
2118. Response to Neoadjuvant Chemotherapy in ICON8: A GCIG Phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment
2120. SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer
2123. Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
2124. Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid tumours
2134. Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: evidence for systemic effects in a phase 2, single-arm study
2143. Evaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade
2146. Patterns of Therapy in Pelvic Lymph Node Positive Prostate Cancer in Europe and Asia: A Real-world Data Analysis
2163. Intermediate prognosis in metastatic germ cell tumors (IPGCT) – Outcome and prognostic stratification
2164. Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial
2179. A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer.
2182. BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701).
2189. Usefulness of the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic cancer and its risk diseases
2190. Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
2207. Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: a UK study
2221. Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B
2224. 9-ING-41, a clinically relevant inhibitor of Glycogen Synthase Kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers
2233. Somatic-stem transition of tumor cells is a key link in the metastasis
2235. Outcomes of Ovarian Clear Cell Carcinoma (OCCC) of the Vall d’Hebron Hospital/Vall d’Hebron Institute of Oncology (VHIO)
2241. Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis
2247. CARRIE: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Istiratumab (MM-141) plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
2249. HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
2250. Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
2260. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
2264. Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)
2275. Genomic Profiling and Matched Therapy for recurrent or metastatic malignant salivary gland tumors
2277. Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer
2278. Treatment Patterns and Overall Survival in Patients With BRAF-Mutated Metastatic Non-Small Cell Lung Cancer
2279. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment
2287. Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
2294. TALAPRO-1: An open-label, response rate phase 2 study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥1 novel hormonal therapy (NHT)
2296. TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer – final results from the randomized phase II trial of the AIO
2298. Corticosteroids administration as a prognostic factor in glioblastoma patients: An Egyptian experience
2299. Neoadjuvant chemotherapy and radical surgery versus chemorradiation for stage IB2, IIA2 e IIB cervical cancer: a randomized controlled trial
2302. Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC)
2304. Impact of postoperative residual tumor and meningeal dissemination in adult medulloblastoma: a retrospective analysis.
2305. Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018
2306. A Phase II Study of Nedaplatin and nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer (KRSG1302)
2307. Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer.
2310. A phase II trial of gemcitabine, S-1 and LV combination therapy in patients with advanced pancreatic cancer
2313. Features Associated with Long-Term Survival in Metastatic Breast Cancer
2320. Interim results from exploratory study to determine S-588410-induced tumor infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
2325. A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)
2327. Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer
2334. Prognostic associations of early prostate-specific antigen (PSA) changes in patients with Metastatic Castration-resistant Prostate Cancer treated with with abiraterone acetate or enzalutamide
2338. Impact of response to preoperative chemotherapy on the outcome of pulmonary metastasectomy for colorectal cancer: Results of a retrospective multicenter study
2339. Quality of life and symptoms in longterm survivors with ovarian cancer: It’s still an issue. Expression VI – Carolin meets HANNA – Holistic Analysis of Long-term survival with Ovarian Cancer: the international NOGGO, ENGOT and GCIG survey
2343. Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
2344. Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
2350. Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib
2352. Phase 1 expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
2354. A prospective observational study of HER2 alterations in NSCLCs: HOT1303-A
2355. FOstering efficacy of anti-PD-1-treatment: nivolumab plus Radiotherapy in advanCEd non-small cell lung cancer - the FORCE trial
2357. Survival Difference Between Microscopically Confirmed and Microscopically Non-Confirmed Cancers
2358. Localablative treatment for synchronous oligometastatic lung cancer – a propensity score analysis of 180 patients
2365. MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma and a nomogram for the prediction of it
2370. Male Breast Cancer: Clinical and Epidemiological Patterns in the United States
2376. Carcinosarcoma: Clinical and Epidemiological Patterns in the United States
2377. OPINION: A single-arm, open-label, Phase IIIb study of olaparib maintenance monotherapy in patients with platinum-sensitive relapsed ovarian cancer and without germline BRCA mutations
2378. Intrinsic and Extrinsic regulation of PD-L2 Expression by transcription factor STAT3 or c-FOS in Oncogene-Driven Non-Small Cell Lung Cancer
2379. Neuropathy and Health Behaviors in Cancer Survivors treated with Chemotherapy (CT)
2381. Age Distribution for Different Types of Cancer in the United States (1996-2015)
2382. The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer
2387. Analysis of the relationship between heading N / L and survival in patients treated with Immunotherapy in lung cancer
2388. Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
2391. Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts
2396. Comparison of acute hematologic and renal toxicities in two chemotherapy schedules of cisplatin for epithelial cell carcinoma of head and neck(A phase II randomized clinical trial)
2414. Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer
2417. Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
2422. Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
2423. Apparent differences in expert recommendations for advanced prostate cancer according to region and medical specialization – analysis of the APCCC 2017 voting results
2425. Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)
2434. Comparison of Patient Populations Identified by Different PD-L1 Assays in Head and Neck Squamous Cell Carcinoma (HNSCC)
2438. Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
2446. Quantifying circulating DNA as a biomarker in clinical practice
2448. Dose-determination results from a Phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
2449. Prognostic value of metabolic tumor volume in recurrent and/or metastatic head and neck squamous cell carcinoma treated with platinum-based chemotherapy.
2452. A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)
2453. In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?
2465. Clinical outcomes and treatment strategies of sarcomatoid carcinoma of the lung
2491. Association Between Patient Reported Quality of Life (QOL) and Survival: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
2494. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: A Retrospective Study of the Merseyside and Cheshire Cancer Network
2497. The impact of inclusion in home palliative program and distance to hospital on chemotherapy near end of life
2498. MORPHEUS: a Phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)–based combinations in different tumour types
2500. A Phase II Study of Preoperative Chemoradiation plus Sorafenib (S) for High-Risk Extremity Soft Tissue Sarcomas (STS)
2504. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic Large Cell Neuroendocrine Carcinoma (LCNEC)
2510. NEO2734 - A novel potent oral dual BET and P300/CBP inhibitor
2512. Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy
2518. Perceptions of Clinical Trial Enrollment in Patients with Bone and Soft Tissue Sarcoma
2521. Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial
2528. CheckMate 592: A Phase 2 Exploratory Study of Biomarkers Associated With the Efficacy of First-line Nivolumab Plus Ipilimumab in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
2532. An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease Associated Renal Cell Carcinoma
2538. Clinicopathological Features of Thymoma with the Expression of Programmed Death-Ligand 1
2539. Oncolytic Virotherapy For Multiple Myeloma Targeting CD40, 41BB and/or IL6R
2543. Kynurenine 3-monooxygenase as a potential biomarker for colorectal cancer
2551. A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy
2553. 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
2555. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
2556. Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer (RAFAELO study)
2558. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: data from a French multicentric cohort
2560. Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study.
2563. Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma; a preliminary analysis of a multicenter, prospective phase II study (BRiZ2012).
2565. Microsatellite instability is associated with distinct clinical and molecular characteristics in early colon cancer: Analysis of a molecular registry of the AIO colorectal study group - Colopredict Plus
2571. Supportive care: patient expectations, availability and uptake
2582. Proteomic Comparison Based on 18FDG-PET/CT Defined Metabolic Tumor Volume in Non-metastatic Nasopharyngeal Carcinoma
2583. Multimodality treatment for pN1 prostate cancer - Adding elective para-aortic radiation in the PART trial
2584. Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective - A real-life analysis.
2586. Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies
2587. Detecting Bone Density in Early Breast Cancer Survivors: The Arm-DXA method
2590. Phase 1/2 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
2595. Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
2596. Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer
2597. Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
2601. Profile of individuals who never undergo colorectal cancer screening
2602. Gliomas diagnosed during 2000-2014 in adults (CONCORD-3): worldwide morphology distribution
2604. Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)
2608. Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer
2609. Imunotherapy in Clinical Practice: Real World Multicentric Brazilian Experience.
2613. Adjuvant radiation therapy leads to an up-regulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) which might contribute to radioresistance in primary breast cancer patients
2615. Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): longer follow-up efficacy and safety data
2623. Prognostic implications of mismatch repair deficiency in patients with early-stage colorectal and endometrial cancer
2628. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)
2631. Real-world outcomes and costs in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
2633. Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Various Gene Alterations and Brain Metastases
2634. Vascular damage and pulmonary function in very long-term survivors of testicular cancer (TC) treated with cisplatin-based chemotherapy (CT)
2638. Can Diffusion Tensor MR Imaging Identify Glioma IDH Mutation Status?
2639. mRNA Expression of ER, PR, HER2 and Ki67 are Concordant to Central IHC and Predict Clinical Outcome: a Validation Study from the ABCSG-6 Biomarker Cohort
2640. Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: results from S-TRAC trial
2646. Impact of BRCA status on outcomes and survival in high-risk early breast cancers
2647. Patient reported outcomes: Web-monitoring versus nurse assessment to improve anticancer therapies?
2649. A three-gene signature to predict lymph node metastasis of pancreatic cancer
2650. Neuroendocrine carcinoma of the urinary bladder: a large analysis of the French GETUG consortium
2651. NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
2657. Interim Results of fight-201, A Phase 2, Open-Label, Multicenter Study of INCB054828 Dosed Intermittently in Patients With Metastatic or Surgically Unresectable Urothelial Carcinoma (UC) Harboring Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) Genetic Alterations
2658. The prognostic value of the Modified Glasgow Prognostic Score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
2663. Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
2665. Influence of enteral nutrition on nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients treated with concurrent chemoradiotherapy: a prospective, multicenter, randomized controlled study
2668. Initial cohort expansion results of sustained arginine depletion with Pegzilarginase in melanoma patients in a Phase 1 advanced solid tumor trial
2674. A Phase 1 study of MEDI1873, a novel GITR agonist, in advanced solid tumors
2675. Comprehensive genomic profiling (CGP) of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors (PMNSGCT)
2680. Fractional polynomial network meta-analysis: a different approach to indirectly assess the comparative efficacy of 2L+ cancer immunotherapy (CIT) treatments for metastatic NSCLC
2685. Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel
2690. Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444
2694. Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors
2695. Impact of the multidisciplinary approach on the survival of squamous head and neck cancer in our institution.
2697. A phase 1/2 study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
2698. Tumor Treating Fields concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase 3 LUNAR study
2704. Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
2711. An international systematic review (SR) of breast cancer (BC) BRCA mutation (BRCAm) prevalence
2713. Joined analysis of Sarcomatoid Carcinoma (SC) mutational profiles: comparison of lung versus head and neck cancer.
2721. Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
2722. Sunitinib tolerance following an initial exposure period: results of longitudinal PRO data from S-TRAC study
2724. Robustness of DLL3 (SP347) Immunohistochemistry Assay for Detection of DLL3 Protein in Small Cell Lung Cancer
2731. Cardiovascular and other competing causes of death among cancer patients, 2006-2015: An Australian population-based study
2735. Significant prognostic markers related to lymphocytes in gastric cancer
2736. Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors
2738. Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
2740. Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy
2741. The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
2752. Comparison of PARPi with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: a network meta-analysis
2753. Phase II trial of perioperative PD-L1 inhibition with Avelumab and mDCF chemotherapy for Resectable Locally Advanced Gastric And Esophago-Gastric Adenocarcinoma
2762. Phase II study of biweekly TPFL induction chemotherapy for locally advanced squamous cell carcinoma of head and neck
2763. Non-small Cell Lung Cancer in Never-smokers – Clinical Characteristics and Outcomes
2770. PERNETTA – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)
2775. Indicators of non-participation in cervical cancer screening: results from the EDIFICE 6 survey
2778. Clinical validation of a NGS-based assay for the detection of BRCA1 and BRCA2 variants in Chinese patients with breast cancer or ovarian cancer
2782. ALK positive Anaplastic large cell lymphoma: molecular diagnosis and minimal residual disease monitoring
2787. The Clinical Features and Genomic Landscape of Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in Patients with Colorectal Cancer
2788. PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study
2797. Phase II study of S-1 and Oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)
2801. Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC)
2806. Benefit from subsequent conventional cytotoxic chemotherapy (CTx) to immunotherapy (IT) in patients (pts) with gynaecological malignancies (GM).
2808. Usability testing of EirV3-a computer-based tool for patient reported outcome measures in cancer
2809. Dynamics of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)
2811. Initial treatment in patients (pts) diagnosed with non-small cell lung cancer (NSCLC) in Denmark from 2005-2015: The SCAN-LEAF study
2814. Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type “window of opportunity”
2815. Pathologic response as a strong predictor of survival irrespective of phenotype in early Breast Cancer
2816. 10-year results of the Breast Cancer Screening Program in Khanty-Mansiysk State Region – Ugra.
2820. Diagnostic Value of Contrast Enhanced Digital Mammography versus Contrast Enhanced MRI for Preoperative Evaluation of Breast Cancer
2822. Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC
2824. TOPNIVO - A safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): first results on behalf of the Unicancer Head&Neck Group and the GORTEC.
2829. The GATTO study: A phase I of the anti-EGFR Tomuzotuximab (TO) in combination with the anti-MUC1 Gatipotuzumab (GAT) in patients with EGFR positive solid tumors.
2830. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in Stage IV NSCLC patients
2832. Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO – A Phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy
2834. Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
2837. Individual network meetings in cancer care - From young people with cancer to adults with brain tumours
2840. Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Cytology Proven Axillary Node-Positive Breast Cancer at Diagnosis
2841. Does the minimal axillary approach lead to lose of prognostic factors in breast cancer?
2847. AYA cancer nursing - An emerging sub-speciality - the first book about AYA cancer nursing, edited and authored by nurses.
2848. The influence of the surgical approach in women diagnosed with breast neoplasia
2858. Tumor response and pain reduction with ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): results from MONALEESA-3
2859. Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
2861. Detection of mutations and copy number alterations in circulating DNA from pancreatic neuroendocrine tumor patients
2864. EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Nationwide register-based cohort study in Sweden
2867. Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial
2869. Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC). A retrospective analysis of the randomized phase I/II Poseidon study.
2870. Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma
2871. 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma
2872. Neoadjuvant Biomarker Research Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast Cancer – the phase II NeoRHEA trial
2873. Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small-cell lung cancer (NSCLC): Results from a Phase 1 expansion cohort (EC 2)
2874. Stromal progesterone receptor expression and long-term survival in patients with resected periampullary adenocarcinoma
2884. Randomized clinical trial of an individualized intervention promotes cancer patients’ prognostic awareness and reduces CPR received in the last month
2885. Genetic screening, counselling, and treatment of BRCA mutation (BRCAm) carriers: a systematic review (SR) of international breast cancer (BC) guidelines
2886. Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: data from KEYNOTE-407
2889. RNA-based analysis of anaplastic lymphoma kinase (ALK) fusions in non-small cell lung cancer (NSCLC) cases showing immunohistochemistry/fluorescence in-situ hybridisation (IHC/FISH) discordance
2891. Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE
2901. A phase 2 study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations
2903. Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects – a multicentre retrospective analysis
2906. Improved Quality of Life in Patients with GEP-NETs Treated with 177Lu-DOTATATE
2909. Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from Arm A of the Phase II BALTIC study
2911. Health-Related Quality of Life (HRQoL) After Progressive Disease (PD) in SPARTAN: a Phase 3 Trial of Apalutamide (APA) Versus Placebo (PBO) in Men with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
2914. Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer
2915. Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)
2916. Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
2917. Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey
2920. Benefits of Physical Activity and Sport integrated into the care pathway of oncology patient.
2922. Safe navigation of CARs in a changing landscape
2925. Pamiparib, a Novel PARP 1/2 Inhibitor, Monotherapy for gBRCAm Patients with Recurrent Ovarian, Fallopian, and Primary Peritoneal Cancer: an Open-label, Multicenter, Phase 2 trial in China
2934. Ribociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompLEEment-1 trial
2935. Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients
2945. Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 Probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
2946. Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors
2949. Understandability of the Standard Arabic Translation of the EORTC QLQ-C15-PAL Questionnaire by Egyptian Patients with Incurable Cancer
2951. Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy
2954. Interim results of fight-202, a phase 2, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
2955. Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)
2956. A Phase I Study of HERV-E TCR Transduced Autologous T Cells (HERV-E TCR T Cells) in Patients (pts) with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
2957. Multicenter Phase II Trial of nab-paclitaxel and Cisplatin (AP) followed by Chemoradiation Therapy (CRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
2958. Gene Expression Profile (GEP) and Survival Among Patients With Advanced Ovarian Cancer
2960. Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
2973. A Prospective Multicenter Study of Primary Breast Lymphoma in the rituximab era: prognostic implication of beta 2 microglobulin and interlukin-6 & interlukin-10
2975. Immune gene expression profiling (GEP) of resected gastric adenocarcinomas (GAs) to identify biomarkers associated with immune checkpoint inhibitor (ICPI) response in early stage disease
2976. Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small-cell lung cancer (NSCLC) patients
2977. Recurrent and Metastatic Carcinomas of the Lacrimal Gland: High Frequency of ERBB2 Driven Disease
2984. IMpower150: clinical safety, tolerability and immune-related adverse events in a Phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
2985. ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort
2989. Potential Drug Cost Impact of Dual Agent Immunotherapy (DAIO) with Nivolumab (N) plus Ipilimumab (I) in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) in Canada.
2990. Baseline lymphocyte counts predict distant recurrence in early breast cancer
2992. Identification of subjects with locally advanced lung cancer who are likely to respond to standard-of-care chemoradiotherapy by a longitudinal monitoring of circulating tumor DNA (ctDNA) using a comprehensive ultra-sensitive NGS assay
2995. Comparing cancer patients’ and support persons’ preferences for the type of consultation and the format of information provided when making a treatment decision
3001. A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)
3003. Evaluation of hypertension and hand-foot syndrome as Markers of anlotinib Efficacy in advanced soft tissue sarcoma
3004. Gene mutation status in circulating tumor DNA (ctDNA) and 1st-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
3016. Histology and detectability on ring-type dedicated breast PET in breast cancer
3021. Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death
3023. Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer
3025. Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): pooled analysis of IMmotion150 and IMmotion151
3029. Alterations in peripheral T cell subsets, T cell Activation Markers and Immune Checkpoint Molecules in advanced Pancreatic Cancer Patients Receiving FOLFIRINOX or Gemcitabine + Nab-Paclitaxel
3030. Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer.
3033. Effects of antibiotic use during immunotherapy in metastatic non small cell lung cancer
3035. Intermittent or continuous Panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): a randomized phase 2 trial (IMPROVE)
3037. Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non small cell lung cancer
3056. The Prognostic Significance of the 2014 International Society of Urological Pathology (ISUP) Grading System in Patients with High-Risk Prostate Cancer
3060. A model using computed tomography-based compactness to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma
3065. The need of re-biopsy: increase in PD-L1 expression from initial stage to recurrence of non-small cell lung cancer
3066. Gender difference in cancer survivors’ perceived information 5-years after diagnosis. Data from the French national study: VICAN 5.
3067. Treatment-Free Interval (TFI) Following Discontinuation of First-Line Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Advanced Renal Cell Carcinoma (aRCC): CheckMate 214 Analysis
3070. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy
3071. PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
3073. The application of indocyanine green fluorescence navigation method to a sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer
3074. Withholding Anti-EGFR: ImpacT on Outcome of RAS wild-type metastatic Colorectal Tumors (WAIT OR ACT): a multicentric AGEO study
3076. Characterization of Response to Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Previously Untreated Advanced Renal Cell Carcinoma (aRCC): CheckMate 214
3077. Development and Validation of a Deep Learning Model using Biomarkers in Pleural Effusion for Prediction of Malignant Pleural Mesothelioma
3078. Pazopanib in advanced or metastatic synovial sarcoma: the Gustave Roussy experience
3081. Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)
3098. Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
3106. Determinants of oncologist’s choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer
3109. RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non–small cell lung cancer: an open-label, multicenter Phase 1b trial
3113. A Phase 1 Study of Oncolytic Immunotherapy of Metastatic Neuroendocrine Tumours using Intralesional Rose Bengal Disodium
3119. The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
3125. Frequency of PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma (HNSCC) in Southern Thailand.
3129. Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset.
3140. Congruence between actual place of death and preferences of Egyptian patients with advanced cancer and their family caregivers
3143. A phase 1b study of safety and preliminary efficacy of extracranial stereotactic body radiation therapy (SBRT) in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy
3156. Ramosetron Versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting
3157. Increased risk of non-germ cell second cancer (SC) after cisplatin-based chemotherapy (CBCT) in 1-year testicular cancer (TC) survivors (TCS)
3159. Determination of DPYD polymorphisms before treatment with chemotherapy with a pyrimidine. Should we continue doing it?
3161. Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed Pseudomyxoma Peritonei
3163. Association of Systemic and Local Inflammation with Prognosis in Rectal Cancer Treated with Neoadjuvant Radiotherapy
3169. Correlation between Immuno-Related Adverse Events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study.
3180. How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience
3184. Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)
3186. Randomized Phase III Study in EBV positive locally advanced nasopharyngeal carcinoma treated with concurrent chemo-radiotherapy with or without Anti-Viral drug.
3194. Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: an exploratory analysis of JCOG1302A
3203. Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
3206. Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: interim analysis of prospective phase II clinical trial
3211. Phase 1b/2 study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
3212. PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
3221. Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma
3222. Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: an analysis of adjuvant TOSCA trial
3224. Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC)
3226. The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice.
3231. Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients. Subgroup analysis from the adjuvant TOSCA trial
3236. Impact of Charlson comorbidity index on survival of octogenarian patients with colorectal cancer.
3240. Hypothyroidism in cancer patients received multikinase inhibitors: Risk Factors and Outcomes
3241. Preoperative Nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): a window-of-opportunity study (NICOLE)
3244. Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
3245. What Information and Features do Young and Older Adults with Cancer Want in their Hospital-based Social Media Cancer Resource?
3247. Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: a retrospective registry-based analysis
3252. First-line Treatment of Desmoid Tumor: Systemic Therapy versus Upfront Surgery
3255. Nintedanib plus docetaxel in routine clinical practice: VARGADO - a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape
3259. Preliminary results of PRINCiPe (Predictors of Resistance to Immunotherapy with Nivolumab [NIVO]) study in advanced pretreated non-small-cell lung cancer (AP-NSCLC), investigating the role of an Immune Genomic Signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
3260. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Ductal Adenocarcinoma Patients Treated with FOLFIRINOX
3262. Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with colorectal liver metastases
3266. A Pan-Cancer Landscape analysis reveals a subset of Endometrial Stromal and Pediatric Tumors defined by Internal tandem duplications of BCOR
3270. Treatment Patterns and Clinical Outcomes of Patients With Locally Advanced and Metastatic Melanoma in a Real-World Setting in China
3271. Chemotherapy-Induced Peripheral Neurotoxicity (CIPN): what are patients telling us?
3272. Association of LIPI Score with Immune Checkpoint Inhibitors (ICI) outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck (R/M SCCHN) patients (pts).
3276. The use of complementary and alternative medicine (CAM) in sarcoma patients
3284. The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients.
3292. Cross-Platform Comparison of NGS and MALDI-TOF for Detecting RAS/RAF/PIK3CA Mutations in Circulating Tumor DNA from metastatic Colorectal Cancer Patient
3294. Foretinib circumvents the NTRK1 G667C mutation-associated entrectinib-resistance in the brain and liver metastases produced by NTRK1 fusion-positive tumor cells
3297. Induction chemotherapy for locally advanced esophageal cancer
3302. Prior or Concurrent Radiotherapy and Nivolumab Immunotherapy in Non-Small Cell Lung Cancer
3303. Everolimus-based therapy versus conventional therapy for refractory breast cancer patients with PI3K/AKT/mTOR mutations
3306. Resistance to anti-PD-1 therapy is associated with the retention of CXCR3+ CD4+ CD8- T cells in blood
3311. The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study
3316. Survival effect of lncRNA-X expression in EGFR-mutant adenocarcinoma
3321. Phase II trial of neoadjuvant therapy using apatinib plus SOX regimen in locally advanced gastric cancer: updated results
3323. The Cancer Molecular Screening and Therapeutics Program (MoST) – A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies
3324. Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer
3327. Evaluation of Progression-Free Survival (PFS) and One-Year (1y) Survival as Surrogate Endpoints (SE) in Previously Treated Advanced Non-Small Cell Lung Cancer (adNSCLC) in the Era of Immuno-Oncology (IO)
3328. A Phase III, Randomized, Open-Label, Multicenter Study of SHR-1210(Anti-PD-1 Antibody) in Combination with Pemetrexed and Carboplatin as First Line Therapy in Subjects with Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer
3329. p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal – A single center retrospective analysis in Japan
3334. A guided and personnalized treatment in metastatic breast cancer: optimisation of gene and protein expression in tumor tissue.
3336. CD13 and CD33 CAR-T cells for the treatment of myeloid malignancies.
3339. Progression-free survival and recurrence results for AGITG DOCTOR. Pre-op cisplatin, 5FU & DOCetaxel +/-radioTherapy after poOR early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma.
3344. P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer
3348. Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?
3351. An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake
3352. GECP 1605/NIVEX TRIAL. Nivolumab in the real world: the SPANISH expanded access program experience in pretreated advanced NSCLC
3360. Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)
3366. Prognostic impact of MSI and 18qLOH in stage II colon cancer: A prospective biomarker study in the SACURA trial
3367. The role of SWI/SNF chromatin remodelling complex ATPase subunit – BRM in TNBC
3369. Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): results from an EORTC led survey
3373. Nomogram for predicting the benefit of surgery for Stage IA-IIB Small-Cell Lung Cancer
3379. PRODIGE 29-UCGI 26(NEOPAN): A Randomised trial of chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC).
3386. Characteristics of the psychosomatic state of patients with lung cancer
3389. Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma
3392. Social and behavioral indicators of undergoing a screening test for lung cancer
3393. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
3398. Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)
3400. Population pharmacokinetics (PPK) of anamorelin (ANAM), an oral selective ghrelin receptor agonist
3401. Nurse led follow-up for CML patients on oral cancer treatment
3405. Working arrangements after cancer diagnosis: who, what, when and how?
3406. STELLAR – Final results of a phase 2 trial of TTFields with chemotherapy for first line treatment of pleural mesothelioma
3408. Interim Results from a Real World European Survey on the Unmet Needs of Patients Living with Metastatic Colorectal Cancer (mCRC)
3412. Phase 1/2 study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3).
3414. Patients’ interpretations and experiences of participation in cancer care
3415. A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)
3417. Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: an observational study in the Netherlands.
3419. Effects of Prednisone on Docetaxel Pharmacokinetics in Metastatic Prostate Cancer: A Randomized Drug-drug Interaction Study.
3422. Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD)
3423. Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: results from CAPRI
3427. The real-world impact of modern treatments on the survival of patients with metastatic melanoma
3431. Should we consider altering our patterns of care for elderly sarcoma patients?
3434. The role of chemotherapy in the landscape of liposarcoma
3436. GEMOX plus hypofractionated radiotherapy for unresectable locally advanced pancreatic cancer: results from a phase 2 study.
3437. Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with oropharyngeal squamous cell carcinoma (OPSCC)
3440. Prospective biomarker study in advanced RAS wild-type colorectal cancer. POSIBA trial.
3441. Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): results from phase II trial (IFCT-1001 CHIVA)
3454. Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy. Combined analysis of two prospective clinical trials
3458. Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer
3466. Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: incidence and outcome
3468. FOLFIRINOX for recurrent pancreatic cancer after resection: nationwide multicenter observational study by Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)
3469. AVEVAC. A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients. (GEMCAD 16-02)
3478. Do Royal Marsden Hospital (RMH) and MD Anderson cancer centre (MDACC) prognostic scoring systems predict survival in patients with Bone sarcoma?
3479. The study of molecular and genetic markers of apoptosis and proliferation, their role in the treatment and prevention of osteogenic sarcoma
3482. A randomized, open-label, non-inferiority study comparing the efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B-cell Non-Hodgkin lymphomas (B-NHL) - AVOID Neutropenia.
3503. Prognostic value of change in neutrophil-lymphocyte ratio during treatment with first-line anti-PD1 therapy in metastatic melanoma
3504. Are treatment recommendations provided by cognitive computing supported by real world data (Watson for Oncology with Cota RWE) concordant with expert opinions?
3506. Short-Term radiotherapy plus chEmotherapy versus Long-term chemoradiotherapy in Locally Advanced Rectal cancer (STELLAR): a planned interim analysis
3509. Kinase Fusions in Colorectal Cancers: A Unique Biologic Subset
3512. Combination of Eribulin plus Gemcitabine in L-Sarcomas
3516. UCHL1 has prognostic relevance and is a therapeutic target in high-grade neuroendocrine lung cancers
3520. Single-cell RNA Sequencing of Triple Negative Breast Cancer Patient-Derived Xenograft Reveals Distinct Cellular Populations Spatially Mapped to Histological Sections
3525. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
3533. Relationship between immune related molecules and chemosensitivity and prognosis in gastric cancer
3534. Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital
3536. Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment
3540. Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. GEM1402.NCT02626962
3551. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study
3557. A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Nivolumab Plus Ipilimumab in Patients (pts) With Localized Renal Cell Carcinoma (RCC) Who Are at High Risk Of Relapse After Radical or Partial Nephrectomy (CheckMate 914)
3559. Prediction of Prostate Cancer Gleason Score Upgrading from Biopsy to Radical Prostatectomy (RP) using a Validated 17-Gene Panel Assay
3560. Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
3562. Efficacy and Safety of Crizotinib in Previously Treated Patients (Pts) with ALK+ Advanced Non-Small-Cell Lung Cancer (NSCLC) aged ≥65 years (y)
3569. Sites of Metastasis and Association with Clinical Outcome (CO) in Advanced Stage Cancer Patients (Pts) Treated with Immunotherapy (IO)
3570. Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases
3577. How to Practice Oncology With a Supportive and Palliative Care Ambulatory Unit: A French Experience (HOASIS)
3581. Geriatric oncology (GO): long term follow-up of a prospective series of the GO Unit, at A. C. Camargo Cancer Center.
3585. Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: looking for prognostic biomarkers
3586. Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma.
3587. Safety of Nintedanib plus Docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: the preliminary results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial
3588. KEYNOTE-151: A Phase 1b Study of Second-Line Pembrolizumab for Chinese Patients With Advanced or Metastatic Melanoma
3600. Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay
3601. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients With Advanced Solid Tumors
3608. Final 42-Month Results from the BOLT Study: Sonidegib Preplanned Subgroup Analyses of Objective Response Rates
3613. Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: a retrospective cohort study
3614. Long-Term Safety of Crizotinib in Previously Treated Patients (Pts) with ALK-positive Advanced/Metastatic Non-Small-Cell Lung Cancer (NSCLC)
3620. Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)
3621. Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer using quantitative proteomics.
3622. Experience in treatment of newly diagnosed multiple myeloma patients with renal failure required dialysis
3623. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project.
3624. Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma
3628. XmaI-RRBS DNA methylation screening resolves breast cancer epigenetic heterogeneity
3629. Settings-Based Efficacy Comparison of Trastuzumab Biosimilars in Breast Cancer: A Systematic Literature Review
3632. Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600–mutant high-grade glioma (HGG) or low-grade glioma (LGG)
3634. Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study
3645. Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor-infiltrating immune cell composition
3647. Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
3651. Advantages of next-generation sequencing in revealing low-level somatic mosaicism in blood samples of retinoblastoma patients
3652. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
3654. Sexual function and quality of life in a national cohort of bilateral testicular cancer survivors
3657. Development and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry
3659. Assesing the effect of telephone support on patients with myeloma Multiple (MM) in The Catalan Oncology Institut in Girona
3661. Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real World Data of 1354 patients with EGFR mutant NSCLC
3666. Immune-related adverse events: comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy.
3672. Incidence of hypocalcemia in a non-inferiority Phase III trial assessing prevention of symptomatic skeletal events (SSE) with Denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)
3674. Prolonged Survival (SV) Associated with Pulmonary Metastasectomy (PM) for Carcinomas of the Cervix (CC)
3677. eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients
3682. Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
3685. The role of modulation of Somatostatin Analogues (SSAs) in association to Peptide Receptor Radionuclide Therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) Entero-Pancreatic Neuroendocrine Tumours (EP-NETs)
3694. The experience of Onco-Palliative care Multidisciplinary Meetings in Hotel Dieu de France University Hospital, an ESMO Designated Center of Integrated Oncology and Palliative Care
3704. A multi-institutional randomized phase II study on the timing of Oxaliplatin plus 5-Fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR Study.
3705. A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
3709. A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): results of PROSPER by age and region
3710. Adriamycin and Ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: results of a retrospective single-center study on 34 patients
3714. Head and Neck (HN) Primary Sarcomatoid Carcinoma (PSC) profile by High-throughput somatic mutation profiling.
3718. Hyperprogression during immuno-checkpoint inhibitors (ICIs): a clinically significant problem?
3721. Phase 1 study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1
3729. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate (NEPC)
3736. “It may not affect you” -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.
3737. Potential clinical management changes in patients harboring locally advanced squamous-cell carcinoma of head and neck by incorporating pre and post chemoradiotherapy 18.FDG PET/CT: A prospective trial.
3739. Relationship between androgen receptor and tumor infiltrating lymphocytes in triple negative breast cancer
3741. KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: does choice of platinum affect outcomes?
3742. Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
3743. Association between efficacy and immune-related adverse events in patients with Non-Small-Cell Lung Cancer receiving immune-checkpoint inhibitors
3744. A Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients
3745. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
3747. HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
3748. Accurate measurement of tumor mutation burden in liquid biopsy (bTMB) using a 500 gene panel
3755. Association between PD-L1 expression and survival in early-stage non-small cell carcinoma
3756. Longitudinal plasma monitoring of subjects treated with EGFR-TKIs allows better understanding of evolution of acquired resistance and can inform optimal treatment strategies
3757. Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1
3762. KEYNOTE-427 Cohort A: Pembrolizumab Monotherapy as First-Line Therapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
3764. Association of immune-related adverse events with immune-checkpoint inhibitors efficacy in patients with solid tumors
3769. Q-TWiST Analysis to Assess Benefit-risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic NSCLC
3770. Everolimus in advanced breast cancer: a systematic review and meta-analysis
3774. Impact of Prognostic Factors and Risk Groups on Overall Survival (OS) in Patients Treated With Pembrolizumab vs Investigator’s Choice Chemotherapy for advanced Urothelial Cancer (UC): Post Hoc Analysis of KEYNOTE-045
3775. Acupuncture for peripheral neuropathy in cancer patients: TCM diagnosis as a predictor of treatment response
3781. Phase 1b/2 study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
3783. Phase II Study of Evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer
3788. Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and MisMatchRepair proteins expression in malignant mesothelioma
3791. Robust detection of MSI from blood circulating tumor DNA (bMSI) to predict the responses of immune checkpoint inhibitors (ICIs) in metastatic gastrointestinal cancers
3796. Intensified 14 day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
3797. The prognostic value of early tumor response in metastatic nasopharyngeal carcinoma patients treated with first-line chemotherapy
3815. Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy
3816. A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
3818. Prevalence of KRAS mutation subtypes and MSI status in Pancreatic Cancer.
3825. Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC)
3826. Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors
3831. A prospective analysis of 30 day mortality following palliative chemotherapy at an Australian tertiary cancer centre.
3832. Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors
3833. Gene expression signature of DNA damage response to predict the prognosis of early stage lung adenocarcinoma
3842. Randomized Phase II Trial of Radium-223 (RA) plus Enzalutamide (EZ) vs. EZ alone in Metastatic Castration Refractory Prostate Cancer (mCRPC)
3846. Utility of Carcinoembryonic Antigen (CEA) in Appendiceal carcinoma
3851. Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab
3853. The incidence of recurrent venous thromboembolism (VTE) and bleeding depending on practical treatment pattern of anticoagulation in the cancer patients with VTE
3857. Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
3861. Neoadjuvant eribulin plus carboplatin vs. paclitaxel plus carboplatin in patients with triple-negative breast cancer (TNBC)
3863. Management of melanoma recurrence following adjuvant anti-PD1 therapy
3869. Venous thromboembolism in Asian patients with pancreatic cancer who underwent palliative chemotherapy: low prevalence, but a poor prognostic factor for early onset
3877. Introducing a new role in cancer care, Coordinating Contact Nurses – patient-reported evaluation.
3881. Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: the RIBANNA study
3883. Breast cancer treatment with everolimus and exemestane in hormone receptor positive/HER2-negative postmenopausal women: final analysis of the French observational TANGO study
3887. First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts). PERSEIDA study
3890. Prognostic impact of anthracyclines and immune/proliferation markers in triple-negative breast cancer according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel plus carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial
3896. Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
3902. Vemurafenib in patients (pts) harboring BRAF V600 mutation. Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial.
3906. Pertuzumab, Trastuzumab and Taxane combination for Visceral Organ Metastatic Patients: Real Life Practice Results
3910. Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer
3913. The Quality Oncology Practice Initiative program: Experience in Spain.
3914. A real world study of apatinib treatment in gastric cancer: current status and clinical benefit
3916. Multicentre, double-blind, randomised Phase II study evaluating gemcitabine with or without Ramucirumab as II line treatment for MPM
3920. Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis
3925. Clinical implication of PDL1 expression and TILs in male breast cancer: More Hype or New Hope? Results from the UMBREAC trial (NCT03240510)
3937. Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer
3939. Soluble PD-L1 as a prognostic factor in advanced acral and mucosal melanoma
3940. Validation of the Clinical AJCC/UICC TNM 8th Edition for Human Papillomvirus Related Oropharyngeal Squamous Cell Carcinoma
3941. Early detection of skeletal muscle atrophy using a multiple plasma-free amino acid index in the advanced aged patients with advanced pancreatic cancer
3945. Safety assessment of the rechallenge by anti-PD-1 or anti-PD-L1 immunotherapy after immune-related adverse events.
3946. High Response Rate with T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a)
3947. Assessment and treatment of breakthrough cancer pain in Spain: a self-audit study
3952. App about chemotherapy - helping the patient with cancer
3956. Long-term Results of Postoperative Chemoradiation Therapy With Capecitabine and Oxaliplatin Versus Capecitabine Alone for Locally Advanced Rectal Cancer: A Randomized, Multicenter, Phase 3 Trial
3959. Multicenter, Phase II Trial of Biweekly S-1, Leucovorin (LV), Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma (mPDAC): Final Report of TCOG T1211 Study
3960. Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab.
3961. The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: preliminary study.
3964. Radium-223 (Ra-223) therapy after abiraterone (Abi): analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
3965. MEDIOLA: A Phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts
3968. Acute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer, a prospective study
3976. A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment
3977. Response to primary treatment for first recurrence independently influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 236 recurrent metastatic patients.
3983. Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)
3985. Systemic Anticancer Therapy Administration Safety
3987. Palliative care in advanced cancer, a clinical and ethical goal achieved?
3990. Phase 2 efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)
3991. Melanoma with brain metastases. Experience of immunotherapy in a single center.
3993. Management of locoregional recurrence after radical resection of a primary non-metastatic retroperitoneal soft tissue sarcoma: results of a retrospective series in a tertiary care center.
4001. Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs
4012. Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients.
4017. Comprehensive biomarker analyses and updated results of PURE-01 study: neoadjuvant pembrolizumab (Pembro) in muscle-invasive urothelial bladder carcinoma (MIBC).
4018. Treatment patterns in patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) in Sweden: The SCAN-LEAF study
4019. PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques – a safety study
4020. Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
4023. The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
4028. TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A.
4032. Prognostic factors of chemo-radiotherapy efficacy in patients with locally-advanced rectal cancer
4034. Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing
4036. Comparative Assessment of Orthotopic Brain Tumor Growth Using Bioluminescence and Magnetic Resonance Imaging
4037. Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from Phase 1 cohorts
4039. Significance of Pretreatment F-18 FDG PET/CT Parameters in Nasopharyngeal Carcinoma Treated with Intensity-modulated Radiation Therapy
4040. CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
4042. The impact of the new TNM classification on survival of patients in stage III non-small cell lung cancer
4048. Contrast enhancement in low grade gliomas: a classic prognostic factor in the molecular age
4050. Development of a Nomogram for Predicting Survival in Microsatellite Stable Patients with Resected Colorectal Cancer
4053. Evaluation of support and information needs for patients with cancer in a Phase I trials unit.
4056. ASTRIS: A real world treatment study of osimertinib in patients with EGFR T790M positive non-small cell lung cancer (NSCLC); European subset
4062. Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
4066. “The German- Registry” of Incidental gallbladder cancer and the GAIN- phase III trial– transformation from a registry to treatment platform due to a trial in trial concept
4068. No benefit of preoperative chemotherapy for primary retroperitoneal sarcomas: results from a single center propensity-matched analysis.
4070. Sentinel lymph node biopsy for clinically N0 oral squamous cell carcinoma
4071. Discordance between HER2 Expression status in Primary Tumor and Matched Malignant Ascites in Gastric Adenocarcinoma
4075. The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
4080. Results of the national organised colorectal cancer screening program with FIT in Paris
4085. Impact of the 8th edition AJCC classification in early stage lung cancer
4089. Sarawak, Healthcare Professionals’ Perception Of Palliative Care at End Of Life
4099. Bald is beautiful: no more. The stigma of alopecia during chemotherapy: Brindisi Oncology Department experience.
4101. A prospective study examining cachexia predictors in patients with incurable cancer.
4109. Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance
4110. Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment
4113. Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
4114. Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial
4120. Clinical Features and Prognosis of Eighty-five Patients with Primary Pulmonary Lymphoepithelioma-like Carcinoma
4125. Realworld prospective data of small biopsy samples for tumor PD-L1 expression in non-small-cell lung cancer
4127. Synergistic anti-cancer effect of Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway
4128. Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer
4132. Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: preliminary results
4133. Comparative Proteomic Analysis of Acetylation Profiles in Esophageal Squamous Carcinoma Cells
4135. Proteomic-based machine learning computational analysis discovered biomarkers of aberrant vesicle-exosomal trafficking to determine chemotherapeutic responses in breast cancer
4136. The Prevalence of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)
4142. Baseline Predictive Factors for efficacy of AntiPD1 used in first line in Melanoma Patients: an Italian Melanoma Intergroup study
4151. Role of FGFR2 amplification in prognosis of patients with ovarian cancer
4152. Circulating exosomal microRNA profiling to depict mechanisms of chemotherapy resistance among triple negative breast cancer
4155. Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)
4158. CA224-047: A Randomized, Double-Blind, Phase 2/3 Study of Relatlimab (Anti–LAG-3) in Combination With Nivolumab (Anti–PD-1) Versus Nivolumab Alone in Previously Untreated Metastatic or Unresectable Melanoma
4162. ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
4169. Body shape trajectories and risk of breast cancer: results from The SUN Study Project
4171. KRAS-dependent and independent mechanisms of progressive disease (PD) in colorectal cancer (CRC) patients (pts) with liver metastases (LM) while monitoring on circulating cell free DNA (cfDNA)
4172. Management and outcome of metastatic breast cancer in men: A comprehensive analysis based on the multi-center national observational ESME (Epidemiological Strategy and Medical Economics) program.
4174. A Phase 1 Trial of Vorolanib (X-82), a Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitor, in Patients (pts) with Advanced Solid Tumors
4175. Intracranial Activity of Ensartinib in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC)
4179. Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value
4190. Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a US-based retrospective observational study of a 200 mg/day starting-dose cohort
4191. C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer
4196. Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompLEEment-1 trial
4202. Phase 1b/2a study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents nuclear β-catenin Translocation in patients with Triple Negative Breast Cancer
4204. Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma
4208. Impact on disease-free survival (DFS) of the surgical waiting time (SWT) for patients (Pts) with early breast cancer (BC)
4209. Brain metastasis in ovarian cancer patients
4215. Clinical characterization of rare EGFR mutations in non-small cell lung cancer and in silico prediction of drug sensitivity
4218. RING observational trial to compare T790M mutation testing in blood by different methodologies
4219. A prospective study of first-line Helicobacter pylori eradication therapy in treating localized extragastric mucosa-associated lymphoid tissue lymphoma
4224. High proportion of prostate cancer survivors continue to experience a negative impact on quality of life long after diagnosis: Patient reported outcomes for an Australian population-based sample.
4225. The HOBOE-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid.
4229. Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
4234. Drug treatment in melanoma: a real-world analysis across Europe and Japan
4244. Impact of tissue processing and interferents on the reproducibility and robustness of a multi-plex gene expression assay measuring tumor inflammation.
4247. Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals
4253. Prevalence and clinical implications of Mismatch Repair (MMR) deficiency in unselected endometrial cancer (EC) patients
4255. The role of comprehensive evaluation for clinical complete response in predicting pathologic complete response in patients treated with neoadjuvant chemoradiation for esophageal squamous cell carcinoma (ESCC)
4257. Proof-of-concept study evaluating a new tool for standardising radiological assessment of tumour response to treatment in routine clinical practice
4258. Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into 2L Cervical Cancer and Solid Tumors
4272. Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer
4274. BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib with continuous schedule vs. cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer